The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2025 | Selecting patients with MDS for transplantation
In this video, Dominiek Mazure, MD, Ghent University Hospital, Ghent, Belgium, briefly comments on the selection of patients with myelodysplastic syndromes (MDS) for stem cell transplantation, highlighting that the majority of patients with this malignancy are older and may not be fit for transplant. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The biggest challenge is of course that the majority of MDS patients are elderly patients that are not quite fit for transplant. The transplant option is only an option for the minority of patients. And of course the treatment approach is risk-based. So in lower-risk MDS, transplant is not necessarily the first choice option because transplant is associated with morbidity and mortality...
The biggest challenge is of course that the majority of MDS patients are elderly patients that are not quite fit for transplant. The transplant option is only an option for the minority of patients. And of course the treatment approach is risk-based. So in lower-risk MDS, transplant is not necessarily the first choice option because transplant is associated with morbidity and mortality. However, in young, very young and fit patients with life-threatening cytopenias, we do offer the transplant. And then for elderly patients, you have to calculate comorbidity, general fitness to see if they are eligible for transplant.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Lecture fees and consultancy fees: Novartis, Incyte, BMS, GSK.
